1Yuen GJ,Morris DM,MydlowPK.Pharmacokinetics,absolute bioavailability and absorption characteristics oflamivudine.J Clin Pharmacol,1995,35(12):1174-1180
2Angel JB,Hussey EK,Hall ST.Pharmacokinetics of 3TC (GR109714X) administered withand without food to HIV-infected patients.Drug invest,1993,6(1):70-74
3Tyrrell DLJ,Mitchell MC,De Man RA.Phase Ⅱ trail of lamivudine for chrinichepatitis B.Hepatology,1993,18(4Pt):112A
4Van leeuwen R,lange JMA,Hussey EK.The safety and pharmacokinetics of a reversetranscriptase inhibitor,3TC,in subjects with HIV indection:a phase Ⅰstudy.AIDS,1992,6(12):1417-1425
5Johnson MA,Horak J,Breuel P.The pharmacokinetics of lamivudine in patients withimpaired hepatic function.Eur J Clin pharmacol,1998,54(4):363-366
8Robert P,Jorge R,Jules et al.Multicenter study of lamivudine therapy for hepatitisB after liver transplantation.Hepatology,1999,29(5):1581-1586
9Lai CL,Ching CK,Tung AKM,et al.Lamivudine is effective in suppressing hepatitis Bvirus DNA in chinese.Hepatitis B surface antigen carriers:A placebo-controlledtrial.Hepatology,1997,25(1):242-244
10Van Leeuwen R,Katlama C,Kitchen V,et al.Evaluation of safety and efficacy of 3TC(lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiencyvirus infection:a phase Ⅰ/Ⅱ study.J Infect Dis,1995,171(5):1166-1171
9Johnson M A, Enkins .t M, Bye C. A sludy of the pharmacokinetic interaction between lamivudine and alpha interferon [J]. Eur J Clin Pharmacol, 2002,56 : 289-292.
10Rita de Cassia E Estrela, Myriam C Salvadori, Renata S I. Raices, et al. Determination of didanosine in human serum by on-line solid-phase extraction coupled to HPLC with electrospray ionization tandem mass spectrometric detection application to a bioequivalcnce study[J]. Journal of Mass Spectrometry, 2003,38:378-385.
